Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Warren

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
The British Journal of Dermatology|August 3, 2018
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Z Z N Yiu, D M Ashcroft, I Evans, et al.
The British Journal of Dermatology|March 18, 2008
Polymorphisms in the PTPN22 region are associated with psoriasis of early onsetRh Ll Smith, R B Warren, S Eyre, et al.
The British Journal of Dermatology|July 10, 2019
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)S K Mahil, N Wilson, N Dand, et al.
BMJ Open|July 14, 2023
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort studyDuc Binh Phan, Hugo Jourdain, Alicia González-Quesada, et al.
The British Journal of Dermatology|February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)D Thaci, S Piaserico, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 16, 2024
Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensusT Torres, N C Brembilla, R G Langley, et al.
The British Journal of Dermatology|April 8, 2021
Defining trajectories of response in patients with psoriasis treated with biologic therapiesN Geifman, N Azadbakht, J Zeng, et al.
The British Journal of Dermatology|January 11, 2019
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic reviewK J Mason, S Williams, Z Z N Yiu, et al.
The British Journal of Dermatology|May 20, 2015
Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions RegisterI Y K Iskandar, D M Ashcroft, R B Warren, et al.
The British Journal of Dermatology|September 21, 2011
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and IrelandP M Laws, A M Downs, R Parslew, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
The British Journal of Dermatology|August 3, 2018
Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Z Z N Yiu, D M Ashcroft, I Evans, et al.
The British Journal of Dermatology|March 18, 2008
Polymorphisms in the PTPN22 region are associated with psoriasis of early onsetRh Ll Smith, R B Warren, S Eyre, et al.
The British Journal of Dermatology|July 10, 2019
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)S K Mahil, N Wilson, N Dand, et al.
BMJ Open|July 14, 2023
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort studyDuc Binh Phan, Hugo Jourdain, Alicia González-Quesada, et al.
The British Journal of Dermatology|February 5, 2021
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)D Thaci, S Piaserico, R B Warren, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 16, 2024
Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensusT Torres, N C Brembilla, R G Langley, et al.
The British Journal of Dermatology|April 8, 2021
Defining trajectories of response in patients with psoriasis treated with biologic therapiesN Geifman, N Azadbakht, J Zeng, et al.
The British Journal of Dermatology|January 11, 2019
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic reviewK J Mason, S Williams, Z Z N Yiu, et al.
The British Journal of Dermatology|May 20, 2015
Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions RegisterI Y K Iskandar, D M Ashcroft, R B Warren, et al.
The British Journal of Dermatology|September 21, 2011
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and IrelandP M Laws, A M Downs, R Parslew, et al.
Pageof 12